Hence, new such applications of GLP-1 drugs are being studied, for Alzheimer's, polycystic ovary syndrome (PCOS), Non-alcoholic fatty liver disease (NAFLD), etc
With off-patent semaglutide and new oral brands emerging from 2026, pharma should leverage FMCG pricing expertise, invest in real-time tracking of patient persistence and switching behaviours, and target drivers of engagement and loyalty beyond price
However, patience is key, as initial darkening may occur before brightening, as explained in the product guidelines
Furthermore, the patients baseline assessment found that he met 9 of the 11 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for AUD